Eli Lilly (LLY) Restructuring Costs (2009 - 2026)

Eli Lilly has reported Restructuring Costs for 18 years, with the latest figure at $279.0 million in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs rose 697.14% year-over-year to $279.0 million; the trailing twelve-month figure through Mar 2026 stood at $728.0 million (down 18.75% YoY), and the FY2025 full-year result was $484.0 million, down 43.79% from the prior year.
• Restructuring Costs for Q1 2026 stood at $279.0 million, up from $84.1 million in the prior quarter.
• The five-year high for Restructuring Costs was $435.0 million in Q2 2024, with the low at $35.0 million in Q1 2025.
• Historically, Restructuring Costs has averaged $193.7 million across 5 years, with a median of $145.3 million in 2022.
• Annual changes were most pronounced in 2025 — Restructuring Costs plunged 75.58% — and 2026, when it jumped 697.14%.
• Eli Lilly's Restructuring Costs stood at $38.1 million in 2022, then jumped by 78.48% to $68.0 million in 2023, then jumped by 406.47% to $344.4 million in 2024, then sank by 75.58% to $84.1 million in 2025, then jumped by 231.75% to $279.0 million in 2026.
• The last three Restructuring Costs figures came in at $279.0 million (Q1 2026), $84.1 million (Q4 2025), and $364.9 million (Q3 2025), per Business Quant data.